Related Experiment Videos
[From inflammation to pain: experimental gene therapy]
Alice Meunier1, Joao Braz, François Cesselin
1Inserm E0331, Inserm U.288, Douleurs et stress, Faculté de Médecine Pitié-Salpêtrière, 91, boulevard de l'Hôpital, 75634 Paris Cedex 13, France.
Medecine Sciences : M/S
|April 7, 2004
Summary
Gene therapy offers new hope for chronic pain by delivering therapeutic proteins to targeted cells. Spinal gene transfer of opioid precursors like proenkephalin A has shown promise in reducing inflammatory and neuropathic pain.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Context:
- Chronic pain is a complex nervous system disease.
- Current treatments for some chronic pain conditions are inadequate.
- Gene-based approaches offer continuous protein production near target cells.
Purpose:
- To explore gene-based therapeutic strategies for chronic pain.
- To evaluate the efficacy of gene transfer for pain management.
- To investigate the potential of targeting pain-processing molecules.
Summary:
- Spinal gene transfer of opioid precursors (proopiomelanocortin, proenkephalin A) attenuated inflammatory and neuropathic pain in animal models.
- Herpes simplex virus vector-mediated proenkephalin A overexpression in sensory neurons reduced pain and inflammation in polyarthritic rats.
- Other molecules, including proinflammatory cytokines, are potential targets for gene-based pain therapies.
Impact:
- Gene therapy shows potential for developing novel treatments for chronic pain.
- This approach may help evaluate new pain-processing molecules for drug development.
- Further research is needed to ensure the safety and clinical applicability of viral vectors.